thiogenesis therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
32 Royal Rd, Belmont, Massachusetts, 024...Phone Number
(647) 846-7766Website
www.thiogenesis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About thiogenesis therapeutics
Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing next-generation sulfur-based therapeutics aimed at treating mitochondrial diseases. Their lead product, TTI-0102, is a novel cysteamine prodrug designed to improve tolerability and bioavailability compared to existing thiol therapies. The company targets pediatric diseases with unmet medical needs, including cystinosis, MELAS, and Leigh syndrome, and plans to initiate pivotal clinical trials in the coming years. With proprietary compounds engineered to overcome previous limitations of thiol-based drugs, Thiogenesis aims to address oxidative stress and inflammation in various inherited and acquired mitochondrial conditions.Explore more
thiogenesis therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is thiogenesis therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
thiogenesis therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if thiogenesis therapeutics had a recent Job posting/layoffs
Check if thiogenesis therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on thiogenesis therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at thiogenesis therapeutics
Product Launch: Get notified when thiogenesis therapeutics launches new products
Check out if thiogenesis therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once thiogenesis therapeutics has new funding data
Recommended Actions
Find VP level buyers at thiogenesis therapeutics
Find more new buyers
Compare Similar Companies to thiogenesis therapeutics
Compare insights from companies similar to thiogenesis therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
thiogenesis therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
thiogenesis therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about thiogenesis therapeutics.
thiogenesis therapeutics financials insights
Gather financial insights about thiogenesis therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$126K
2026
Private Equity
$29K
thiogenesis therapeutics Tech Stack
A closer look at the technologies used by thiogenesis therapeutics
thiogenesis therapeutics News & Media
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - August 1, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased...OTC Markets Group Welcomes Thiogenesis Therapeutics, Corp. to OTCQX
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), a clinical-stage biotech company, has qualified to trade on the OTCQX® Best Market. Thiogenesis Therapeutics Corp. upgraded to OTCQX from the Pink® market.Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing compounds for unmet pediatric diseases, announced today that its CEO, Dr. Patrice Rioux, has been invited to lead a roundtable discussion on redox signaling at the 6th Annual Mitochondria Symposium at UCLA, in Los Angeles, California, on December 8, 2023.Reactive oxygen species ("ROS").Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases, today announced the addition of Vincent Stanton Jr., MD to its Scientific Advisory Board ("SAB"). Dr. Stanton was a co-founder of Thiogenesis Therapeutics, Inc., dating back to February 2016.Dr. Vincent Stanton Jr., MD is an entrepreneur and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding thiogenesis therapeutics
Sign Up For FreeTo access detailed company insights
Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing next-generation sulfur-based therapeutics aimed at treating mitochondrial diseases. Their lead product, TTI-0102, is a novel cysteamine prodrug designed to improve tolerability and bioavailability compared to existing thiol therapies. The company targets pediat... Read More
